{
  "success": true,
  "sourceFile": "C:\\Users\\panik\\Documents\\GitHub\\Protcol2USDMv3\\input\\trial\\NCT03627767_JADE_MONO2\\NCT03627767_JADE_MONO2_SAP.pdf",
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33,
    34,
    35,
    36,
    37,
    38,
    39
  ],
  "modelUsed": "gemini-3-flash-preview",
  "sapData": {
    "analysisPopulations": [
      {
        "id": "pop_1",
        "name": "Full Analysis Set - Open Label",
        "text": "This is the set of all subjects who received at least one dose of study treatment during the open label run-in phase.",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "label": "FAS-OL",
        "populationDescription": "This is the set of all subjects who received at least one dose of study treatment during the open label run-in phase.",
        "criteria": "Received >=1 dose of study treatment during open label run-in phase"
      },
      {
        "id": "pop_2",
        "name": "Full Analysis Set - Randomized",
        "text": "This is the set of all subjects who have been randomized at Week 12 and have received at least one dose of study treatment within the double-blind phase. By study design, this will be a subset of FAS-OL. Subjects are assigned to the randomized treatment group regardless of actual treatment received.",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "label": "FAS-RA",
        "populationDescription": "This is the set of all subjects who have been randomized at Week 12 and have received at least one dose of study treatment within the double-blind phase. By study design, this will be a subset of FAS-OL. Subjects are assigned to the randomized treatment group regardless of actual treatment received.",
        "criteria": "Randomized at Week 12 AND received >=1 dose of study treatment within the double-blind phase"
      },
      {
        "id": "pop_3",
        "name": "Per Protocol Analysis Set",
        "text": "The Per Protocol Analysis Set (PPAS) is a subset of the FAS-RA and will include all randomized subjects who did not have any major protocol deviations. The specific criteria for exclusion from the PPAS will be finalized and documented prior to unblinding.",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "label": "PPAS",
        "populationDescription": "The Per Protocol Analysis Set (PPAS) is a subset of the FAS-RA and will include all randomized subjects who did not have any major protocol deviations. The specific criteria for exclusion from the PPAS will be finalized and documented prior to unblinding.",
        "criteria": "Subset of FAS-RA AND no major protocol deviations"
      },
      {
        "id": "pop_4",
        "name": "Safety Analysis Set",
        "text": "The Safety Analysis Set (SAF) is defined as all subjects who receive at least one dose of the investigational product. Safety will be assessed by the spontaneous reporting of AEs, physical examinations, and clinical laboratory results.",
        "populationType": "Safety",
        "instanceType": "AnalysisPopulation",
        "label": "SAF",
        "populationDescription": "The Safety Analysis Set (SAF) is defined as all subjects who receive at least one dose of the investigational product. Safety will be assessed by the spontaneous reporting of AEs, physical examinations, and clinical laboratory results.",
        "criteria": "Received >=1 dose of investigational product"
      }
    ],
    "characteristics": [
      {
        "id": "char_1",
        "name": "Age",
        "code": "AGE",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Age",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "Age category used for stratification (<18 years and >=18 years)"
      },
      {
        "id": "char_2",
        "name": "Eczema Area and Severity Index",
        "code": "ECZEMA_AREA_AND_SEVE",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Eczema Area and Severity Index",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "EASI score used to define response and flare"
      },
      {
        "id": "char_3",
        "name": "Investigator’s Global Assessment",
        "code": "INVESTIGATOR’S_GLOBA",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Investigator’s Global Assessment",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "IGA score (5-point scale) used to assess disease severity"
      },
      {
        "id": "char_4",
        "name": "Body Weight",
        "code": "BODY_WEIGHT",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Body Weight",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "Weight in kg, inclusion criterion requires >=40 kg"
      }
    ],
    "summary": {
      "populationCount": 4,
      "characteristicCount": 4
    }
  }
}